Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase III Trial of Adjuvant Cemiplimab in Patients With Resected Stage II-IIIA NSCLC Who Have Not Received Prior Adjuvant Chemotherapy

NCT06931717 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT06931717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06931717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase III Trial of Adjuvant Cemiplimab in Patients With Resected Stage II-IIIA NSCLC Who Have Not Received Prior Adjuvant Chemotherapy
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 3
Overall status
Recruiting
Start date
January 12, 2026
Completion date
March 31, 2029
Enrollment
390 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer